Research programme - ROR gamma t inhibitors - Orca Pharmaceuticals/AstraZenecaAlternative Names: ROR inhibitors - Orca Pharmaceuticals/AstraZeneca; RORγt inhibitors - Orca Pharmaceuticals/AstraZeneca
Latest Information Update: 03 Mar 2015
At a glance
- Originator Orca Pharmaceuticals
- Developer AstraZeneca; Orca Pharmaceuticals
- Class Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders